My Watchlist
Indicators
Silicon Valley 150
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

127.00 -0.80 (-0.63%)
Streaming Delayed Price Updated: 4:00 PM EDT, Sep 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Deep Dive Into Jazz Pharmaceuticals Stock: Analyst Perspectives (9 Ratings)
 
Via Benzinga
Beyond The Numbers: 5 Analysts Discuss Jazz Pharmaceuticals Stock
 
Via Benzinga
Q2 Rundown: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Other Pharmaceuticals Stocks
As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its... 
Via StockStory
Topics Artificial Intelligence Intellectual Property
JAZZ Q2 Deep Dive: Pipeline Milestones and Oncology Headwinds Shape Outlook
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.1% year on year to $1.05 billion. The company’s outlook for the full year was... 
Via StockStory
Retail Traders Cheer Jazz Pharma After FDA Clears Rare Drug For Brain Tumor
Via Stocktwits
Earnings Scheduled For August 5, 2025
 
Via Benzinga
The Analyst Verdict: Jazz Pharmaceuticals In The Eyes Of 11 Experts
 
Via Benzinga
Earnings Scheduled For May 6, 2025
 
Via Benzinga
Preview: Jazz Pharmaceuticals's Earnings
 
Via Benzinga
Why Jazz Pharmaceuticals (JAZZ) Stock Is Trading Up Today
Shares of biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) jumped 4.8% in the afternoon session after the company received accelerated approval from the U.S. Food and Drug Administration (FDA) for... 
Via StockStory
Topics Artificial Intelligence
Jazz (JAZZ) Q2 Revenue Rises 2%
Via The Motley Fool
Topics Intellectual Property
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) Recognized as a Decent Value Stock with Strong Fundamentals
Jazz Pharmaceuticals (JAZZ) is a value stock with strong fundamentals, trading below industry averages in P/E and EV/EBITDA, while maintaining high profitability and steady growth potential. 
Via Chartmill
Jazz Pharmaceuticals (NASDAQ:JAZZ) Reports Q2 In Line With Expectations But Stock Drops
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) met Wall Street’s revenue expectations in Q2 CY2025, with sales up 2.1% year on year to $1.05 billion. The company’s outlook for the full year was... 
Via StockStory
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Reports Q2 2025 Earnings Miss and Leadership Transition
Jazz Pharmaceuticals Q2 2025 results miss revenue and EPS estimates, shares drop 6%. New CEO Renee Gala takes helm amid Xywav growth but investor concerns linger. 
Via Chartmill
Topics Earnings
Jazz Pharmaceuticals (JAZZ) To Report Earnings Tomorrow: Here Is What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings this Tuesday after the bell. Here’s what investors should know. 
Via StockStory
Topics Artificial Intelligence
2 Top Stocks I Wouldn't Hesitate to Invest $1,000 in Right Now
Via The Motley Fool
Where Jazz Pharmaceuticals Stands With Analysts
 
Via Benzinga
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.
All four companies are testing out orexin agonists to improve the symptoms of narcolpesy. 
Via Investor's Business Daily
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
Acadia Emerges From Behind The Scenes With A Potential $12 Billion Opportunity
Acadia Pharmaceuticals is working on its next-generation Nuplazid and, for CEO Catherine Owen Adams, the journey is personal. 
Via Investor's Business Daily
Topics Intellectual Property
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching
JAZZ Pharmaceuticals (NASDAQ:JAZZ) appears undervalued with strong profitability and decent growth, making it a candidate for value investors. Check the full analysis for details. 
Via Chartmill
Avadel Shareholder Seeks Board Shakeup, Citing Millions Lost On Lumryz
ASL demands Avadel replace its board over failures in marketing Lumryz and urging a review of strategic options 
Via Benzinga
JAZZ PHARMACEUTICALS PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching
JAZZ Pharmaceuticals (NASDAQ:JAZZ) is an undervalued biopharma stock with strong profitability, reasonable financial health, and steady growth, making it a candidate for value investors. 
Via Chartmill
Jazz Pharma's Zepzelca Combo Shows Survival Edge In Lung Cancer Study
Jazz Pharma's Zepzelca plus Tecentriq significantly improved survival in a Phase 3 study for extensive-stage small-cell lung cancer patients. 
Via Benzinga
Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) – An Undervalued Biopharmaceutical Stock Worth Watching
Jazz Pharmaceuticals (NASDAQ:JAZZ) appears undervalued with strong profitability and reasonable growth, making it a potential pick for value investors. 
Via Chartmill
JAZZ Q1 Earnings Call: Revenue and Profit Miss, Product Pipeline Drives Outlook
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s... 
Via StockStory
Topics World Trade
Pharmaceuticals Stocks Q1 In Review: Jazz Pharmaceuticals (NASDAQ:JAZZ) Vs Peers
As the Q1 earnings season wraps, let’s dig into this quarter’s best and worst performers in the pharmaceuticals industry, including Jazz Pharmaceuticals (NASDAQ:JAZZ) and its peers. 
Via StockStory
Topics Artificial Intelligence Intellectual Property
Jazz Pharmaceuticals (NASDAQ:JAZZ) Misses Q1 Sales Targets
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) fell short of the market’s revenue expectations in Q1 CY2025, with sales flat year on year at $897.8 million. On the other hand, the company’s... 
Via StockStory
Earnings To Watch: Jazz Pharmaceuticals (JAZZ) Reports Q1 Results Tomorrow
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting results tomorrow after market close. Here’s what to expect. 
Via StockStory
Topics Artificial Intelligence
Jazz Pharmaceuticals (JAZZ) Reports Earnings Tomorrow: What To Expect
Biopharma company Jazz Pharmaceuticals (NASDAQ:JAZZ) will be reporting earnings tomorrow afternoon. Here’s what to look for. 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.